High-throughput, automated analysis of viral vector titer and process-related impurities accelerates downstream process development of AAV-based gene therapies

Cell & Gene Therapy Insights 2022; 8(9), 1079;

DOI: 10.18609/cgti.2022.159

Published: 30 September 2022
FastFacts


Watch the video or read the poster to learn:

  • How to use a single, automated platform for both viral vector titer and impurity analysis
  • Why fully automated, microfluidic immunoassays provide a time- and sample-saving alternative to ELISA techniques
  • How to deploy a strategy for shortening analysis time, reducing sample volume, and dramatically increasing walkaway time

Justine Collet-Brose after graduating from the University of Grenoble Alpes (France) in Biotechnological Medicines and Management, Justine worked 6 years in a Swiss Biotech company developing therapeutic antibodies. Having had the chance to support a biotherapeutic program from the preclinical phase to the FDA market approval, she then decided to join Gyros Protein Technologies as Field Application Specialist supporting customers in Europe on various bioanalytical area including bioprocess, preclinical/clinical development, vaccines and cell and gene therapies. With more than 10 years of experience on the Gyrolab technology, she recently joined the Product and Market Management team to keep contributing to address academia and industry needs in the development of innovative treatments.